LAKE FOREST, Calif.,
Feb. 17, 2015 /PRNewswire/ --
Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of
advanced cryogenic logistics solutions for the life sciences
industry, serving markets including immunotherapies, stem cells,
cell lines, clinical research organizations, vaccine manufacturers,
animal health, and reproductive medicine, today announced the
launch of a new logistics service supporting complete facility
relocation of critical cryogenically frozen sample collections.
Cryoport is providing complete logistics management for the
relocation of a leading research laboratory and IVF clinic, with
all material shipping and transport supervised and performed by
trained personnel under compliance with DOT, CDC and IATA
regulations.
The relocation of a laboratory or clinic is a significant and
complex endeavor consisting of valuable and irreplaceable research
samples such as cell lines, DNA, and other biological samples such
as an individual's reproductive material critical for family
creation. The critical nature of these samples requires full
regulatory knowledge under an umbrella of exact environmental
conditions for the transfer. Cryoport has the best-in-class
logistics solutions and possesses the expertise in handling to
safely and successfully relocate cryogenically frozen samples
without error.
Jerrell Shelton, Cryoport's CEO,
stated, "We are uniquely suited to support the wholesale movement
of critical laboratory samples that require strict conditions from
one location to another in a controlled manner. The fact that
institutions and clinics trust their entire life's work to our care
is a testament to our validated cryogenic logistics solutions
paired with our experience and knowledge in supporting such
relocations. We look forward to further collaboration with leading
research centers and other organizations in their relocation over
the coming months."
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics
solutions to the life sciences industry through its purpose-built
proprietary packaging, information technology and specialized cold
chain logistics expertise. We provide leading edge logistics
solutions for biologic materials such as immunotherapies, stem
cells, CAR-T cells, and reproductive cells for clients worldwide
including points-of-care, CRO's, central laboratories,
pharmaceutical companies, contract manufacturers, and university
researchers. Our packaging is built around our proprietary Cryoport
Express® liquid nitrogen dry vapor shippers, which are
validated to maintain a constant -150°C temperature for a 10 day
dynamic shipment duration. Our information technology centers
around our Cryoportal™ Logistics Management Platform, which
facilitates management of the entire shipment process. Cryoport is
the preferred cryogenic logistics solutions partner to the world's
largest shipping companies controlling more than 85% of the world's
air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers
access to SEC documents, press releases, videos, audiocasts and
more, please click to download from your iPhone and iPad
or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely
historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the company's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
company's cash flow, market acceptance risks, and technical
development risks. The company's business could be affected by a
number of other factors, including the risk factors listed from
time to time in the company's SEC reports including, but not
limited to, the annual report on Form 10-K for the year ended
March 31, 2013. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. Cryoport, Inc.
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
Logo -
http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cryoport-launches-new-logistics-service-supporting-facility-relocation-of-cryogenically-frozen-sample-collections-300036809.html
SOURCE Cryoport, Inc.